BioStock:Targinta takes lead in the ADC field in the Nordics

Targinta has selected the first ADC drug candidate, TARG9, which is armed with a powerful toxin, primarily for the treatment of triple-negative breast cancer and glioblastoma. With this, the company is established as a leading player in the Nordics in the field of so-called antibody-drug conjugates. BioStock dives deep into the potential and benefits of the ADC technology.

Read the full article at biostock.se :

https://www.biostock.se/en/2022/05/targinta-takes-lead-in-the-adc-field-in-the-nordics/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se